30 November 2015 - Boehringer Ingelheim (Canada) Ltd. and Eli Lilly Canada announced today that Health Canada has approved Jardiance (empagliflozin) to be used as an adjunct to diet and exercise to improve glycemic control in adult patients with type 2 diabetes mellitus.

For more details, go to: http://www.boehringer-ingelheim.ca/en/news/press_releases/2015/30Nov2015.html